2026 Q1 -tulosraportti
9 päivää sitten
‧43 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 päivää sittenIs this stock exchange closed today? Can't find any info about it anywhere.
·2 päivää sittenYes, it is Constitution Day in Denmark, so most of the country is shut down.
·3 päivää sittenNow, data is coming soon. Which parameters are the most important and how high do the numbers need to be before they don't disappoint?·2 päivää sitten · Muokattu@milf_hunter69 Thanks for the comprehensive answer. It makes sense that the dose is small from the start. I assume that data later in the year will show the effect on the tumor's impact to a greater extent. Is that correctly assumed? And is there a limit to what one would call good data in %? Let's assume that we hit 90% of tumors, and at the same time 10% surrounding tissue? Would that be approved in your eyes? The reason I ask is that it's nice to hear people's hopes in advance because otherwise it's easy afterwards to just say, well, the data is super good.
2 päivää sitten · Muokattu2 päivää sitten · MuokattuI ended up looking around a bit further, and a TBR of 2 seems to be the minimum value we should hope for. If it's above 3, then it's should be getting some attention from the big pharmaceutical companies. If it's above 5, then we should see the acquisition we all dream of.
·3 päivää sittenI know it's impossible to predict, and several here write that it could go all the way up to 500 if everything goes perfectly with Curasight, but what would a realistic price be at the end of the year if everything still goes as planned🤗
·2 päivää sittenWell, one must also be a bit aware of the psychology. An old Chinese proverb says: "Have little and receive much. Have much and become confused." It seems, however, that the proverb has been short-circuited regarding many investors - because solely through the expectations of receiving much, they appear distinctly confused.
·3 päivää sittenIt's probably a long weekend soon, regarding Curas? Exciting many days where there's no possibility to trade, but news can probably still drop....even though it's raining all weekend and it's not exactly shorts weather...😆
·3 päivää sittendo you have pexa also allani?
·3 päivää sittenMax 26 days until preliminary biodistribution and dosimetry data are published...insanely exciting! Inderes' latest analysis overview lists several investment reasons in Curasight: 1: The market for uTREAT (where Curasight does not yet have a partnership agreement) is estimated to be 25x larger than uTRACE. (FYI: Curasight has a 70mio usd uTRACE partnership agreement with Curium for prostate cancer alone....what could it potentially amount to when uTREAT is calculated...) 2: First patient data in January showed very promising signs with "high tumour uptake + retention of up to 24 hours". 3: Big Pharma focuses (and invests/acquires) in the RLT sector...and moves quickly...even on companies that only have limited data available. Will it be an acquisition or a partnership for Curasight? 4: There are four important readouts before the end of the year. Add to that an (expected) increased market attention/interest, adjusted price targets and precisely speculation in acquisitions (and at a minimum, partnerships). 5: As a first-in-class treatment, Curasight can get by with smaller (and cheaper) clinical trials. This potentially also means a treatment that comes to market faster... Still reading..? :) Then drop a comment, whether you are short or long in the company + what expectations you have for the rest of the year & possibly, how long you have followed the case.
·2 päivää sittenActually, it wasn't "up to 24 hours" - it was "at least 24 hours" - and that's great. :)·2 päivää sitten · MuokattuYou are absolutely right; just had to re-read the PM from January :) https://www.curasight.com/news/press-releases/2026/curasight-announces-encouraging-preliminary-data-from-phase-1-trial-evaluating-first-in-class-radiopharmaceutical-utreat-in-high-grade-gliomas/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
9 päivää sitten
‧43 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 päivää sittenIs this stock exchange closed today? Can't find any info about it anywhere.·2 päivää sittenYes, it is Constitution Day in Denmark, so most of the country is shut down.
- ·3 päivää sittenNow, data is coming soon. Which parameters are the most important and how high do the numbers need to be before they don't disappoint?·2 päivää sitten · Muokattu@milf_hunter69 Thanks for the comprehensive answer. It makes sense that the dose is small from the start. I assume that data later in the year will show the effect on the tumor's impact to a greater extent. Is that correctly assumed? And is there a limit to what one would call good data in %? Let's assume that we hit 90% of tumors, and at the same time 10% surrounding tissue? Would that be approved in your eyes? The reason I ask is that it's nice to hear people's hopes in advance because otherwise it's easy afterwards to just say, well, the data is super good.2 päivää sitten · Muokattu2 päivää sitten · MuokattuI ended up looking around a bit further, and a TBR of 2 seems to be the minimum value we should hope for. If it's above 3, then it's should be getting some attention from the big pharmaceutical companies. If it's above 5, then we should see the acquisition we all dream of.
- ·3 päivää sittenI know it's impossible to predict, and several here write that it could go all the way up to 500 if everything goes perfectly with Curasight, but what would a realistic price be at the end of the year if everything still goes as planned🤗·2 päivää sittenWell, one must also be a bit aware of the psychology. An old Chinese proverb says: "Have little and receive much. Have much and become confused." It seems, however, that the proverb has been short-circuited regarding many investors - because solely through the expectations of receiving much, they appear distinctly confused.
- ·3 päivää sittenIt's probably a long weekend soon, regarding Curas? Exciting many days where there's no possibility to trade, but news can probably still drop....even though it's raining all weekend and it's not exactly shorts weather...😆·3 päivää sittendo you have pexa also allani?
- ·3 päivää sittenMax 26 days until preliminary biodistribution and dosimetry data are published...insanely exciting! Inderes' latest analysis overview lists several investment reasons in Curasight: 1: The market for uTREAT (where Curasight does not yet have a partnership agreement) is estimated to be 25x larger than uTRACE. (FYI: Curasight has a 70mio usd uTRACE partnership agreement with Curium for prostate cancer alone....what could it potentially amount to when uTREAT is calculated...) 2: First patient data in January showed very promising signs with "high tumour uptake + retention of up to 24 hours". 3: Big Pharma focuses (and invests/acquires) in the RLT sector...and moves quickly...even on companies that only have limited data available. Will it be an acquisition or a partnership for Curasight? 4: There are four important readouts before the end of the year. Add to that an (expected) increased market attention/interest, adjusted price targets and precisely speculation in acquisitions (and at a minimum, partnerships). 5: As a first-in-class treatment, Curasight can get by with smaller (and cheaper) clinical trials. This potentially also means a treatment that comes to market faster... Still reading..? :) Then drop a comment, whether you are short or long in the company + what expectations you have for the rest of the year & possibly, how long you have followed the case.·2 päivää sittenActually, it wasn't "up to 24 hours" - it was "at least 24 hours" - and that's great. :)·2 päivää sitten · MuokattuYou are absolutely right; just had to re-read the PM from January :) https://www.curasight.com/news/press-releases/2026/curasight-announces-encouraging-preliminary-data-from-phase-1-trial-evaluating-first-in-class-radiopharmaceutical-utreat-in-high-grade-gliomas/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
2026 Q1 -tulosraportti
9 päivää sitten
‧43 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 päivää sittenIs this stock exchange closed today? Can't find any info about it anywhere.·2 päivää sittenYes, it is Constitution Day in Denmark, so most of the country is shut down.
- ·3 päivää sittenNow, data is coming soon. Which parameters are the most important and how high do the numbers need to be before they don't disappoint?·2 päivää sitten · Muokattu@milf_hunter69 Thanks for the comprehensive answer. It makes sense that the dose is small from the start. I assume that data later in the year will show the effect on the tumor's impact to a greater extent. Is that correctly assumed? And is there a limit to what one would call good data in %? Let's assume that we hit 90% of tumors, and at the same time 10% surrounding tissue? Would that be approved in your eyes? The reason I ask is that it's nice to hear people's hopes in advance because otherwise it's easy afterwards to just say, well, the data is super good.2 päivää sitten · Muokattu2 päivää sitten · MuokattuI ended up looking around a bit further, and a TBR of 2 seems to be the minimum value we should hope for. If it's above 3, then it's should be getting some attention from the big pharmaceutical companies. If it's above 5, then we should see the acquisition we all dream of.
- ·3 päivää sittenI know it's impossible to predict, and several here write that it could go all the way up to 500 if everything goes perfectly with Curasight, but what would a realistic price be at the end of the year if everything still goes as planned🤗·2 päivää sittenWell, one must also be a bit aware of the psychology. An old Chinese proverb says: "Have little and receive much. Have much and become confused." It seems, however, that the proverb has been short-circuited regarding many investors - because solely through the expectations of receiving much, they appear distinctly confused.
- ·3 päivää sittenIt's probably a long weekend soon, regarding Curas? Exciting many days where there's no possibility to trade, but news can probably still drop....even though it's raining all weekend and it's not exactly shorts weather...😆·3 päivää sittendo you have pexa also allani?
- ·3 päivää sittenMax 26 days until preliminary biodistribution and dosimetry data are published...insanely exciting! Inderes' latest analysis overview lists several investment reasons in Curasight: 1: The market for uTREAT (where Curasight does not yet have a partnership agreement) is estimated to be 25x larger than uTRACE. (FYI: Curasight has a 70mio usd uTRACE partnership agreement with Curium for prostate cancer alone....what could it potentially amount to when uTREAT is calculated...) 2: First patient data in January showed very promising signs with "high tumour uptake + retention of up to 24 hours". 3: Big Pharma focuses (and invests/acquires) in the RLT sector...and moves quickly...even on companies that only have limited data available. Will it be an acquisition or a partnership for Curasight? 4: There are four important readouts before the end of the year. Add to that an (expected) increased market attention/interest, adjusted price targets and precisely speculation in acquisitions (and at a minimum, partnerships). 5: As a first-in-class treatment, Curasight can get by with smaller (and cheaper) clinical trials. This potentially also means a treatment that comes to market faster... Still reading..? :) Then drop a comment, whether you are short or long in the company + what expectations you have for the rest of the year & possibly, how long you have followed the case.·2 päivää sittenActually, it wasn't "up to 24 hours" - it was "at least 24 hours" - and that's great. :)·2 päivää sitten · MuokattuYou are absolutely right; just had to re-read the PM from January :) https://www.curasight.com/news/press-releases/2026/curasight-announces-encouraging-preliminary-data-from-phase-1-trial-evaluating-first-in-class-radiopharmaceutical-utreat-in-high-grade-gliomas/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt